Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiaping Li

Showing results (161-170 of 192) with videos related to

Pageof 20
Sort By:
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|April 26, 2022
The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasionZhenwei Peng, Xiaoxue Wu, Jiaping Li, et al.
Radiology|February 2, 2018
Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency AblationZhenwei Peng, Shuling Chen, Mengchao Wei, et al.
Cancer Medicine|July 6, 2024
DEB-TACE versus cTACE for unresectable HCC with B1-type bile duct invasion after successful biliary drainage: A propensity score matching analysisWenzhe Fan, Xinlin Zheng, Xiao Zhao, et al.
European Radiology|April 24, 2021
Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPSWenzhe Fan, Jian Guo, Bowen Zhu, et al.
Journal of Cancer Research and Clinical Oncology|July 5, 2022
Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolizationWenzhe Fan, Bowen Zhu, Xinlin Zheng, et al.
JAMA Oncology|June 20, 2024
Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical TrialWenzhe Fan, Bowen Zhu, Shuling Chen, et al.
Cancer Medicine|March 14, 2019
Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinomaShuling Chen, Huilin Jin, Zihao Dai, et al.
Pathology, Research and Practice|December 23, 2019
miR-593-5p inhibit cell proliferation by targeting PLK1 in non small cell lung cancer cellsLiang Yan, Yizonheng Zhang, Kai Li, et al.
Journal of Translational Medicine|August 3, 2020
Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumorsJiaping Li, Wei Jiang, Jinwang Wei, et al.
Ecotoxicology and Environmental Safety|July 9, 2024
Cr (VI)-induced ribosomal DNA copy number variation is associated with semen quality impairment: Evidence from human to animal studyJing Huang, Zhaoqiang Jiang, Zheng Ruan, et al.
Pageof 20

Showing results (161-170 of 192) with videos related to

Sort By:
Pageof 20
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|April 26, 2022
The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasionZhenwei Peng, Xiaoxue Wu, Jiaping Li, et al.
Radiology|February 2, 2018
Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency AblationZhenwei Peng, Shuling Chen, Mengchao Wei, et al.
Cancer Medicine|July 6, 2024
DEB-TACE versus cTACE for unresectable HCC with B1-type bile duct invasion after successful biliary drainage: A propensity score matching analysisWenzhe Fan, Xinlin Zheng, Xiao Zhao, et al.
European Radiology|April 24, 2021
Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPSWenzhe Fan, Jian Guo, Bowen Zhu, et al.
Journal of Cancer Research and Clinical Oncology|July 5, 2022
Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolizationWenzhe Fan, Bowen Zhu, Xinlin Zheng, et al.
JAMA Oncology|June 20, 2024
Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical TrialWenzhe Fan, Bowen Zhu, Shuling Chen, et al.
Cancer Medicine|March 14, 2019
Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinomaShuling Chen, Huilin Jin, Zihao Dai, et al.
Pathology, Research and Practice|December 23, 2019
miR-593-5p inhibit cell proliferation by targeting PLK1 in non small cell lung cancer cellsLiang Yan, Yizonheng Zhang, Kai Li, et al.
Journal of Translational Medicine|August 3, 2020
Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumorsJiaping Li, Wei Jiang, Jinwang Wei, et al.
Ecotoxicology and Environmental Safety|July 9, 2024
Cr (VI)-induced ribosomal DNA copy number variation is associated with semen quality impairment: Evidence from human to animal studyJing Huang, Zhaoqiang Jiang, Zheng Ruan, et al.
Pageof 20